10.30.17
CMP Pharma’s CaroSpir, the first FDA-approved oral liquid dosage form of the potassium-sparing diuretic spironolactone, is now available. CaroSpir was approved on August 4.
CaroSpir oral suspension is for adult patients who have difficulty swallowing, or who cannot swallow tablets. It provides a stable and consistent dose of spironolactone. Previously, patients that required a liquid form of spironolactone have had to rely on unapproved pharmacy compounded formulations, which typically have limited shelf life, are not quality control tested for potency and sterility/bioburden.
“CaroSpir is intended for a subset of the patient population that needs spironolactone, but has difficulty swallowing or inability to swallow. Until today there was no FDA-approved oral suspension of spironolactone to satisfy this unmet need. The availability of CaroSpir now gives healthcare providers and appropriate patients a convenient, safe and approved liquid option,” said Gerald Sakowski, chief executive officer of CMP Pharma, Inc.
CaroSpir oral suspension is for adult patients who have difficulty swallowing, or who cannot swallow tablets. It provides a stable and consistent dose of spironolactone. Previously, patients that required a liquid form of spironolactone have had to rely on unapproved pharmacy compounded formulations, which typically have limited shelf life, are not quality control tested for potency and sterility/bioburden.
“CaroSpir is intended for a subset of the patient population that needs spironolactone, but has difficulty swallowing or inability to swallow. Until today there was no FDA-approved oral suspension of spironolactone to satisfy this unmet need. The availability of CaroSpir now gives healthcare providers and appropriate patients a convenient, safe and approved liquid option,” said Gerald Sakowski, chief executive officer of CMP Pharma, Inc.